Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Allergan, Inc.    AGN   US0184901025

ALLERGAN, INC. (AGN)

30
Delayed Quote. Delayed Nyse - 09/19 09:38:09 am
169.84 USD   -0.08%
1d ago ALLERGAN : Actress And Tv Star Kyle Richards Diagnosed With A Type Of Chron..
1d ago ALLERGAN : to cut its workforce by 13%
1d ago ALLERGAN : Assigned Patent
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Allergan, Inc. : CORRECT : Allergan 4Q Net Rose 6.3%, Margins Improve; R&D Costs Higher

02/02/2012 | 11:30am US/Eastern
Recommend:
0

("Allergan 4Q Net Falls 6.3% On Higher R&D Costs; Margins Improve," at 9:41 a.m. EST, misstated the earnings change direction in the headline and first and fourth paragraphs. A corrected version follows:)

Allergan Inc.'s (>> Allergan, Inc.) fourth-quarter earnings rose 6.3% and margins improved, though the Botox maker saw a sharp rise in research-and-development costs and booked one-time items.

The company also forecast current-quarter earnings of 84 cents to 86 cents a share on revenue of $1.34 billion and $1.39 billion, while analysts surveyed by Thomson Reuters expect 91 cents on $1.38 billion. Allergan also expects full-year earnings of $4.13 to $4.19 a share on revenue between $5.65 billion and $5.85 billion. Analysts were expecting $4.21 a share on $5.89 billion for the year.

Allergan has seen its revenue grow for more than two years, aided by surging sales of the wrinkle-fighting drug Botox. The injectable neurotoxin is approved for both cosmetic use and for treating various medial issues. Allergan has been expanding its pipeline of late, such as buying Vicept Therapeutics Inc., the developer of a cream to treat rosacea, and striking a deal with Map Pharmaceuticals Inc. (>> MAP Pharmaceuticals Inc.) to jointly promote Map's experimental migraine treatment Levadex. Allergan's Botox was also approved in August as a treatment for urinary incontinence in patients with neurologic conditions such as spinal-cord injury and multiple sclerosis.

Allergan reported a profit of $279.8 million, or 90 cents a share, up from $263.1 million, or 85 cents, a year earlier. Excluding items such as amortization, realignment and litigation costs, earnings rose to $1 a share from 88 cents. Revenue jumped 7.1% to $1.4 billion.

Its October projection was earnings of 97 cents to 99 cents a share on sales of $1.33 billion to $1.41 billion.

Operating margin rose to 29.2% from 28.1%.

Research and development costs jumped 13% to $226.4 million.

Specialty pharmaceutical sales--which make up the bulk of Allergan's revenue--rose 8.9%. Revenue from the medical-device segment, which includes breast implants and the Lap-Band System for obesity, decreased 1%.

Shares were trading 1.9% lower at $85.63 premarket. The stock has risen 4.7% over the past three months through Wednesday's close.

 
   -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com 

Stocks mentioned in the article : Allergan, Inc., MAP Pharmaceuticals Inc.
Recommend :
0
React to this article
Latest news on ALLERGAN, INC.
1d ago ALLERGAN : Actress And Tv Star Kyle Richards Diagnosed With A Type Of Chronic Dr..
1d ago ALLERGAN : to cut its workforce by 13%
1d ago ALLERGAN : Assigned Patent
2d ago ALLERGAN : Researchers Submit Patent Application, "Extended Release Biodegradabl..
2d ago ALLERGAN : Patent Application Titled "Compounds Act at Multiple Prostaglandin Re..
3d ago ALLERGAN : reaches truce with suitors on special shareholder meeting
3d agoDJU.S. HOT STOCKS : Hot Stocks to Watch
3d ago ALLERGAN : agrees to move forward with meeting
3d ago ALLERGAN : Botox maker to slash 25 Irish posts
3d ago ALLERGAN : Botox job cuts ; companies today
Advertisement
Chart
Duration : Period :
Allergan, Inc. Technical Analysis Chart | AGN | US0184901025 | 4-Traders
Income Statement Evolution
Allergan, Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF